Thrombophilia Treatment Market Trends

Growth Drivers

• Healthcare quality improvement and cost-effective interventions: According to a study conducted by the Agency for Healthcare Research and Quality in 2022, early intervention can lower hospitalization rates by 22.2%, saving USD 1.31 billion in the U.S. healthcare costs. Hospitals are adopting structured VTE risk models, further driving the demand for early anticoagulation intervention and thrombophilia screening. Also, the early intervention of anticoagulants can eliminate clots and reduce complications. This further lowers the ICR admission cases and mortality rates. Governments are conducting exhaustive thrombophilia screening to identify patients at risk of recurrent VTE.
• Government spending and reimbursement policies: The Medicare spending in the U.S. in 2023 reached USD 2.89 billion on anticoagulants. There has been increased emphasis on the screening and early anticoagulation strategies to prevent exorbitant VTE complications. For instance, the Affordable Care Act in the U.S. incentivizes preventive screening by indirectly boosting the testing procedures. Other than this, India and Brazil are introducing exemplary VTE prevention strategies, further bolstering the demand for thrombophilia tests. The enhanced reimbursement support has raised the test volumes, and various pharmaceutical and diagnostic companies are investing in the research and development of thrombophilia testing.
• The advent of telemedicine and home testing: According to the Agency for Healthcare Research and Quality, 65.4% of the thrombophilia patients utilize INR monitoring, lowering clinic visits by 31%. These innovations are enhancing the patient's access to care and early diagnosis. Telemedicine is allowing patients to consult hematologists without any delay, and virtual follow-ups lower the hospital visits, making long-term more convenient. Also, telemedicine has been widely adopted as it lowers healthcare costs by reducing unnecessary hospitalization and lab testing. Telemedicine-based care is growing exponentially as the cases of deep vein thrombosis are rising.

Challenges

• Pricing caps and regulatory approval delays: Numerous health systems impose stringent price controls on the anticoagulants to put constraints on the budget. In Germany, the Arzneimittelpreisverordnung incorporates reference pricing limits for direct oral anticoagulants. These factors force the manufacturers to negotiate steep discounts to handle access.  

• Exorbitant costs for the patient: The expenses demotivate patient adherence, lowering the screening rates and restricting the treatment accessibility. Genetic and lab tests can cost up to USD 210- USD 1510 without insurance. Numerous insurers don’t cover thrombophilia screening until the presence of recurrent DVT is present, leaving asymptomatic patients at risk.